CERES NANOSCIENCES — Department of Defense SBIR Phase II: SB112-005

Description

Immune marker panel tests can provide significant information for understanding and addressing many areas of health and wellness and disease conditions. However, conducting large clinical studies to identify the significance of panel based biomarkers has been hampered primarily by the logistics of acquiring quality samples from clinical subjects and extracting and measuring the valuable markers on the downstream analytical platforms.Additionally, the transition from clinical study to clinical test has been hampered by the lack of consistent technologies and methodologies used for both settings. The Nanotrap technology can address both of these requirements.Ceres Nanosciences proposes to develop a technology platform to address the need for both improved sample collection methods, extraction protocols and improved downstream detection limits (>100-fold improvement) of low-abundance and highly labile cytokines as part of an immunome panel. A baseline immunome study will be completed using the developed technology to assess immunome biomarker levels in healthy patients over a one year period.